Related Experiment Video
Updated: Jul 7, 2026
08:53
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Managing relapsed and refractory Hodgkin lymphoma
1HDJ Hématologie, Hopital Saint-Louis, Paris, France.
British Journal of Haematology
|February 19, 2008
Summary
Relapsed Hodgkin lymphoma (HL) requires risk-stratified treatment. Prognostic factors guide therapy, with autologous stem-cell transplantation (ASCT) crucial for intermediate/unfavorable groups.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Hodgkin lymphoma (HL) has high curability, but some patients experience treatment failure or relapse.
- Identifying prognostic factors at relapse is crucial for guiding subsequent management.
Purpose of the Study:
- To review prognostic factors at relapse in Hodgkin lymphoma.
- To establish treatment guidelines for relapsed HL based on prognostic stratification.
Main Methods:
- Review of literature on prognostic factors and treatment strategies for relapsed HL.
- Classification of relapsed patients into distinct prognostic groups (favorable, intermediate, unfavorable).
Main Results:
- Prognostic factors at relapse include duration of remission and extranodal disease/stage.
- Primary refractory HL patients belong to the unfavorable prognostic group.
- Second-line chemotherapy response is critical; ASCT benefits intermediate/unfavorable groups.
Conclusions:
- Treatment decisions for relapsed HL should be guided by prognostic factors.
- ASCT may not be necessary for all relapsed HL patients, particularly those with late relapse and early-stage disease.
- High-dose therapy and ASCT are recommended for chemosensitive intermediate/unfavorable relapse patients; tandem HDT or allogeneic SCT considered for refractory cases.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...